MedPath

Angitia Incorporated Limited

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

Phase 2
Recruiting
Conditions
Postmenopausal Osteoporosis
Interventions
Other: Placebo
First Posted Date
2024-08-29
Last Posted Date
2025-05-18
Lead Sponsor
Angitia Biopharmaceuticals
Target Recruit Count
350
Registration Number
NCT06577935
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Del Sol Research Management, LLC, Tucson, Arizona, United States

🇺🇸

Center for Advanced Research & Education, Gainesville, Georgia, United States

and more 16 locations

A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

Phase 3
Recruiting
Conditions
Degenerative Disc Disease
Interventions
Drug: Placebo
First Posted Date
2023-11-03
Last Posted Date
2024-01-03
Lead Sponsor
Angitia Biopharmaceuticals
Target Recruit Count
400
Registration Number
NCT06115512
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

Phase 1
Completed
Conditions
Osteogenesis Imperfecta
Interventions
Drug: Placebo
First Posted Date
2023-10-17
Last Posted Date
2025-01-10
Lead Sponsor
Angitia Incorporated Limited
Target Recruit Count
72
Registration Number
NCT06086613
Locations
🇺🇸

Orange County Research Center, Lake Forest, California, United States

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

Phase 1
Completed
Conditions
Degenerative Disc Disease
Interventions
Drug: Placebo
First Posted Date
2022-10-10
Last Posted Date
2022-10-10
Lead Sponsor
Angitia Biopharmaceuticals
Target Recruit Count
60
Registration Number
NCT05574543
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

and more 3 locations

A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: Placebo
First Posted Date
2022-02-07
Last Posted Date
2024-02-05
Lead Sponsor
Angitia Biopharmaceuticals
Target Recruit Count
90
Registration Number
NCT05225857
Locations
🇦🇺

Q-Pharm Pty Ltd, Brisbane, Queensland, Australia

🇦🇺

Nucleus Network Pty Ltd., Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath